Turel, Canan Akünal2023-04-102023-04-1020222792-0542http://doi.org/10.33631/sabd.1052875https://search.trdizin.gov.tr/yayin/detay/1124733https://hdl.handle.net/20.500.12684/12071Aim: The aim of this study was to evaluate the effects of different clinical applications of BoNT-A as hemifacial spasm, blepharospasm, cervical dystonia, bruxism, head tremor and spasticity in stroke, Multiple Sclerosis (MS), spinal trauma, hereditary spastic paraplegia, cerebral palsy, and chronic migraine. Material and Methods: In this retrospective study, which was conducted between January 2019 and December 2021, 79 patients with movement disorders, spasticity, and chronic migraine monitored in our clinic and whose BoNT-A injections were applied were included. The diagnosis and treatment, side effects encountered in therapy, follow-up during the treatment, and the response to the treatment evaluated subjectively by patients were discussed. Results: The improvement in patients' response to treatment was subjectively reported by themselves. The improvement in the response of the patients to the treatment subjectively stated that improvement of 60% and above was taken as good, improvement between 59-40% moderate, and improvement of 39% and below bad. Accordingly, 78.94% of the patients subjectively stated improvement as good, 13.15% as moderate, and 7.89% as bad. Although the incidence of complications was 9.21%, these side effects were mild and transient in all of the patients and did not cause any of the patients to discontinue the treatment. Conclusion: The results were statistically significant and consistent with the literature. This study supports the fact that botulinum toxin therapy is effective and safe for HS, BS, cervical dystonia, spasticity, bruxism, head tremor, and chronic migraine.en10.33631/sabd.1052875info:eu-repo/semantics/openAccessBotulinum Toxinblefpharospasmdystoniahemifacial spasmspasticityArticle1234014061124733